Guggenheim Reiterates Buy on Insmed, Raises Price Target to $52
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Vamil Divan has reiterated a 'Buy' rating on Insmed (NASDAQ:INSM) and raised the price target from $50 to $52.
September 05, 2023 | 4:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guggenheim analyst Vamil Divan has reiterated a 'Buy' rating on Insmed and raised the price target from $50 to $52. This could potentially lead to an increase in the stock's price.
The reiteration of a 'Buy' rating and an increase in the price target by a reputable analyst like Vamil Divan could potentially lead to an increase in the stock's price as it signals confidence in the company's future performance. This news is highly relevant and important for investors in INSM.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100